Reports Q4 revenue $13.8M, consensus $11.56M. “I am extremely proud of our team’s commitment and hard work this past year. We transformed quite a bit at Exagen and together, we are steering the company towards profitability, with a sharp focus on increasing ASP while diligently driving down expenses and responsibly managing cash. The progress we’ve made in the past year has significantly bolstered the health of our organization. We look forward to serving our clinicians and patients in 2024 with a renewed organization which is very much focused on reaching our operating goals. Our strategy has been validated and I’m confident that the best is yet to come for Exagen,” said John Aballi, President and Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XGN:
- XGN Earnings this Week: How Will it Perform?
- Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
- Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference